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Dextromethorphan hydrobromide (DM) sustained release matrix pellets containing 10% w/w drug were 
prepared by an extrusion/spheronization technique. The effect of mixing different concentrations of ethyl 
cellulose (EC), hydroxypropyl methylcellulpse (HPMC K10), and Carbopol 934 with Avicel PH101 on 
the rheological properties of pellet wet mass was evaluated using mixer torque rheometry (MTR). The 
prepared pellets were characterized for size, drug content, and in‑vitro DM release rate. The results showed 
that increasing the concentration of the hydrophobic polymer (EC) with Avicel PH101 decreased wet 
mass consistency, represented by mass mean line torque. Lower binder ratio was required for optimum 
wet massing, while mixing with swellable polymers (HPMC and Carbopol) caused a noticeable increase 
in both mean line torque and binder ratio. Combinations of HPMC and Carbopol at higher concentrations 
resulted in controlled in vitro release of DM from the prepared pellets. Furthermore, mathematical 
treatment of the in vitro release data of DM from the prepared pellets showed that all formulations 
except those containing 5% Carbopol plus 5% HPMC (F10) follow first order release. n values of these 
formulation were in the range of 0.09‑0.40, which support an anomalous non‑Fickian release. 
Keywords: Dextromethorphan hydrobromide. Matrix pellets. Extrusion spheronization. Mix torque 
rheometer (MTR). 
INTRODUCTION
Pellets as a dosage form have several drug delivery 
and technological benefits in comparison to the conventional 
single‑unit regimen. Less irritation of the gastro‑intestinal 
tract and a lowered risk of side effects due to dose dumping 
are achieved by formulating drugs as pellets (Bechgaard, 
Nielsen, 1978). In addition, formulation and technological 
advantages are realized with pellets, such as better flow 
properties, low friability, narrow particle size distribution, 
ease of coating, and uniform packing. It was shown that 
pellets, as multi‑unit dosage forms, have started to gain 
acceptance over conventional single units, for controlled 
release purposes (Mehta et al., 2001). The rapid and 
homogenous dispersion of pellets in the gastrointestinal 
tract results in maximized drug absorption, and reduces the 
fluctuations that may prevail in plasma levels. Therefore, 
the potential drug side effects associated with plasma 
level changes can be minimized without lowering drug 
bioavailability. Additionally, owing to the homogeneous 
absorption from spherical multiparticulate systems, pellets 
minimize fluctuations in gastric emptying rates as well 
as overall transit times. Thus, minimization of both intra 
and inter‑subject variations in plasma levels of single‑unit 
regimens could be achieved. 
The application of pellet‑ and granule‑based 
controlled drug delivery systems was investigated by 
several studies. It is recommended to avoid the use of 
organic solvents or coating due to strict global requests of 
product safety. Industrial hygiene rules and FDA guidelines 
are being strengthened, restricting solvent use and exposure 
(Ibrahim, 2013). Furthermore, monitoring the coating 
procedures is tedious, and frequently encounters large 
variability (Heng, 2005). Many alternative techniques 
were studied for controlled drug delivery systems such as 
melt granulation (Schaefer, Holm, Kristensen, 1990), melt 
extrusion (Sprockel et al., 1997; De Brabander, Vervaet, 
Remon, 2003), melt dispersion (Follonier, Doelker, Cole, 
1994), and melt solidification (Siepmann et al., 2006). In 
addition, development of matrix sustained release pellets 
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saves time and money by omitting the coating procedure 
(Ghali, Klinger, Schwartz, 1989). Such systems retard 
the penetration of aqueous fluids into the formulation and 
hence slow the rate of drug release.
The rheological properties of pellets’ wet masses 
could affect the release rates from pellet formulations. 
These properties can be effectively assessed by a mixer 
torque rheometer (Chatlapalli, Rohera, 2002; Soh, Liew, 
Heng, 2006). Ibrahim (2013) showed that an inverse 
relation was observed between the rheological character 
of pellet wet mass (expressed by peak torque) and in vitro 
release rate of mefenamic acid from sustained release 
matrix pellets. Additionally, the results obtained by 
Ibrahim and Shazly (2014) revealed that diclofenac sodium 
release from pellets was governed by the molecular weight 
of PEG used, since increasing the molecular weight of 
PEG resulted in slowing the drug release rate from pellets, 
while increasing its concentration enhanced the release 
rate. This was attributed to increasing the peak torque of 
pellet wet mass by increasing PEG molecular weight and 
lowering it by increasing PEG level.
Dextromethorphan hydrobromide (DM) is a non‑
narcotic antitussive agent generally used as an ingredient 
in cough and cold remedies. The drug is a white crystalline 
powder with a molecular weight of 370.3, and its water 
solubility is 15 mg/mL at 25 °C (Budavari, 1996). The 
dosage of the drug is usually three to four times a day 
because of its short half‑life (2.7 h). Therefore, DM 
sustained release dosage forms were developed to avoid 
repeated administration, and to increase patient compliance 
(Pongjanyakul et al., 2005). Bharag, Taka and Sakr 
(2006a) reported that extended‑release DM matrix tablets 
were developed using HPMC K100LV/ methacrylic acid 
copolymer (Eudragit® L100‑55) combination, and polyvinyl 
acetate–povidone (PVAP). Both selected extended‑release 
DM matrix tablets followed square root of time‑dependent 
kinetics for drug release, indicating a diffusion-controlled 
release mechanism. In another study, Bharag, Taka and 
Sakr (2006b) reported that the selected extended‑release 
HPMC/Eudragit and PVAP dextromethorphan tablets 
were not bioequivalent to the marketed capsule product, 
TussHustenstiller Retardkapslen®. However, the tablets had 
improved bioavailability as shown by area under the curve 
(0–∞). The aim of the present study was to investigate the 
effect of different polymers on the dextromethorphan HBr 
matrix pellets wet massing properties, particle size and drug 
release rate.
MATERIAL AND METHODS
DM was kindly supplied by RIYADH PHARMA 
(Riyadh, Saudi Arabia). Microcrystalline cellulose (Avicel® 
PH‑101) was purchased from Serva Feinbiochemica, 
(Heidelberg, Germany). Ethylcellulose (EC) was gifted 
by Colorcon (United Kingdom). High viscosity‑grade 
hydroxypropyl methylcellulose, Methocel K10;HPMC, 
was kindly donated by DOW (Midland, MI, United 
States). Carbopol 934 was obtained from Goodrich 
chemical Co. (England).
METHODOLOGY
Characterization of pellets wet masses by mixer 
torque rheometer
The wet mass before pelletization procedures 
(extrusion/spheronization) was evaluated by the mixer 
torque rheometer (MTR). MTR consists of a 135‑mL 
capacity stainless‑steel bowl equipped with two mixing 
blades with a rotational speed of 20–150 rpm (MTR‑3, 
Caleva, Dorset, England). A sample of 15–30 g of dry 
powder mixture is sufficient to cover the mixer blades in 
accordance to the powder bulk density. With the help of 
a torque arm connected from the main body of the mixer 
to a calibrated load transducer, the wet mass torque was 
measured directly on the mixer bowl. For all studies, a 
mixer speed of 50 rpm was applied. Data acquisition and 
analyses were performed using software provided by the 
equipment manufacturer.
Individual powder ingredients were homogeneously 
mixed using turbula mixer (type S27, Erweka, Apparatebau, 
Germany). Fifteen grams of dry powder blend was used 
in the wet massing studies. Two milliliters of binder 
solution (water in this study) was added at intervals over 
12 wet massing cycles, each wet massing cycle consisted 
of a one‑minute mixing period and a 20‑second torque 
data logging. The values of mean line torque (NM) were 
monitored during the wet massing procedures.
Preparation of pellets (extrusion/spheronization 
procedures)
The compositions of different pellet formulations 
containing 10% w/w DM are illustrated in Table I. Water 
was used as a binder solution for the formation of wet mass 
prior to extrusion/spheronization to prepare DM‑loaded 
pellets. The choice of the water volume required for wet 
massing was based on the highest torque value observed 
by MTR. Formula weights of the active ingredient and 
the other pellet excipients were homogeneously mixed 
in turbula mixer, and the powder mixture was wetted 
with a suitable volume of water. Thereafter, the wet mass 
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was extruded at a speed of 90 rpm with a screen pore 
size of 1 mmØ (Mini Screw Extruder, Model MSE1014, 
Caleva, Dorset, England). The resulting extrudates were 
spheronized in a spheronizer (Model 120, Caleva, Dorset, 
England) at a rotation speed of 700 rpm, for 5 minutes in a 
rotating plate of regular cross‑hatch geometry. Pellets were 
then placed on a tray and dried in a hot oven at 50‑60°C 
for 6 hours. 
Drug content
The prepared pellets were characterized for their 
DM content in triplicate. In brief, a specific weight of 
pellets was crushed in a porcelain mortar and about 20 mg 
of the powder was dispersed in 500 mL phosphate buffer 
(pH=6.8) under sonication for 10 minutes. The dispersion 
was then filtered using a cellulose nitrate filter with pores 
of 0.2 μm in diameter (Sartorius, Göttingen, Germany) 
and the absorbance was measured spectrophotometrically 
at 278 nm (UV‑2800 spectrophotometer, Labomed Inc., 
USA). Drug content was computed from the standard 
curve.
Particle size analysis
DM‑loaded, sustained release matrix pellets were 
investigated for their size distribution using laser light 
diffraction technique (Mastersizer Scirocco 2000, Malvern 
Instruments, Grovewood Road, U. K.). A pellet sample 
weight of about 300 mg was introduced to the sample micro 
feeder. All samples were analyzed 5 times and average 
results were taken. The pellets 10th (d(0.1)), 50th (d(0.5)) 
and 90th (d(0.9)) percentiles were used to characterize the 
pellets size distribution. The approximate mean diameter 
was taken as the average of d(0.1), d(0.5), and d(0.9) values.
To investigate the pellet particle size distribution, the 
span value was calculated from the equation given below 
(Chen et al., 2004). Small values of span refer to a narrow 
particle size distribution. 
Span = [d (0.9) – d (0.1)] / d (0.5)
In vitro dissolution studies
The dissolution rate studies for DM‑loaded pellets 
were performed using the USP dissolution basket method 
(apparatus 1). Pellets weighing equivalent to 50 mg DM 
were added to 500 mL of dissolution medium (phosphate 
buffer, pH 6.8). The temperature was maintained at 
37 ± 0.5 °C. An accurately weighed amount of the prepared 
pellets was added to each flask. For each sample formula, 
drug dissolution was analyzed in triplicate and absorbance 
was measured spectrophotometrically at 278 nm up to 6 
hours. The percentage of drug released was determined as 
a function of time using a calibration curve constructed at 
the same wavelength.
Statistical analysis
The results were analyzed by using the software 
GraphPad Prism5 (GraphPad Software, La Jolla, USA) 
applying one‑way ANOVA. Differences between 
formulations were considered to be significant at p≤0.05.
RESULTS AND DISCUSSION
Characterization of pellet wet masses by mixer 
torque rheometer
Wet mass studies of Avicel PH101 mixed with 
different concentrations of EC, HPMC, and Carbopol 
(using water as the binder liquid) were conducted to 
determine the water/powder ratio required to attain a 
maximum torque value for powder wet massing prior to 
extrusion/spheronization procedures. The MTR curve 
of Avicel PH101 itself showed the progress of liquid 
saturation phases. The mean torque value of Avicel PH101 
wet mass was found to increase by increasing the added 
binder volume. Different mean line torque patterns were 
TABLE I - Composition of various DM pellet formulations 
Ingredient (%w/w)
Pellet formulations
F0 F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11
EC 5 10 20
HPMC K10 5 10 20 5 10
Carbopol 934 5 10 20 5 10
DM 10 10 10 10 10 10 10 10 10 10 10 10
Avicel PH101 90 85 80 70 85 80 70 85 80 70 80 70
Water (Binder) QS
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exhibited in case of Avicel PH101‑EC systems, Figure 1. 
A noticeable decrease of MTR curve area was observed 
upon increasing the EC weight ratio. This results from 
progression to liquid saturation phase, which prevails at 
lower water/powder ratio. The lowest peak torque value 
was recorded in case of the Avicel PH101‑EC system 
containing 20% EC (0.279 Nm). Additionally, the water/
powder ratio (mL/g) required for peak torque for Avicel 
PH101‑EC systems was found to be less than that of Avicel 
PH101 alone (Figure 1). However, the water/powder ratios 
(mL/g) for all Avicel PH101‑EC systems were the same 
for all EC weight ratios (1: 1 mL/g; Figure 1). Figure 2 
illustrates the MTR patterns of Avicel PH101‑HPMC 
systems. Binary system containing 5% and 10% HPMC 
exhibited high peak torque values (1.428 Nm and 1.612 
Nm, respectively) in comparison to Avicel PH101, but 
10% HPMC caused reduction of the binder ratio in contrast 
to that recorded with the system containing 5% HPMC or 
Avicel PH101 alone (Figure 2). Mixing HPMC with Avicel 
PH101 in 20% w/w resulted in formation of a very sticky 
mass at a low binder ratio (0.67 mL/g).
The MTR patterns of Carbopol‑Avicel PH101 
systems showed that by increasing Carbopol weight ratio, 
an increase in the wet mass peak torques was observed 
(Figure 3). In addition, lower binder ratio (1: 1 mL/g) was 
observed for the wet mass of Avicel PH101 mix containing 
10% Carbopol. It is worth noting that Avicel PH101‑
Carbopol system containing 20% Carbopol showed very 
high viscosity when mixed with the binder solution that 
was difficult to be measured by the MTR. Parker, Rowe 
and Upjohn (1990) showed that the magnitude of binding 
liquid, when spreading and wetting the powder, and the 
interaction with the granulating liquid, are responsible for 
controlling the relative positions of peak values for mean 
line torque. Pendular and funicular wet massing phases are 
characterized by a gradually increasing network of liquid 
bridges. These two phases together are expected to result 
in an increase in powder mass cohesiveness and, in turn, 
an increased torque on the mixer (Parker, York, Rowe, 
1990; Luukkonen et al., 1999). In case of filling all the air 
spaces in the granular material with the binding liquid, the 
capillary phase was attained at the maximum on the curve. 
Further addition of the binding liquid caused a decrease in 
wet mass torque value, as a slurry of particles dispersed 
in liquid is formed. 
Pellet sizes
Table II illustrates the sizes of the prepared pellet 
formulations using laser45 diffractometry represented by 
the computed values of volume weighted mean particle 
size and the d (0.1), d (0.5) and d (0.9). The average 
values of the volume weighted means for all pellet 
formulations were found between 1242.7 µm‑878.5 µm 
with small span values (0.62‑0.94) indicating a narrow 
particle size distribution and high pellet sphericity (Sinha 
et al., 2010). In case of pellet formulae containing EC 
(F1‑F3), increasing EC weighted ratio resulted in reduced 
size of the prepared pellets. In contrast, increasing the 
HPMC concentration in pellet formulations (F4‑F6) was 
accompanied by increasing the pellets’ sizes. Moreover, 
FIGURE 1 - Effect of different concentrations of EC on mean 
torque of Avicel PH101® wet masses.
FIGURE 2 - Effect of different concentrations of HPMC K10 on 
mean torque of Avicel PH101® wet masses.
FIGURE 3 - Effect of different concentrations of Carbopol on 
mean torque of Avicel PH101® wet masses.
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the pellet formulations containing Carbopol showed that 
increasing Carbopol level from 5% to 10% resulted in 
increasing the pellet size, which could be attributed to 
the increased torque value of pellets wet mass containing 
10% Carbopol more than that contains 5% (Figure 3). It 
is worth mentioning that the pellet formula containing 
20% Carbopol (F9) showed irregular shapes due to the 
very high wet mass consistency, and therefore, the particle 
size was not determined for such formula. Furthermore, 
in case of pellet formulations containing blends of HPMC 
and Carbopol (F11 and F12), increasing the level of each 
polymer in the blend resulted in increasing the pellet size. 
Ibrahim (2013) showed an inverse relation between the 
peak torque of the pellets wet masse and size. Moreover, 
Kristensen, Schæfer and Kleinebudde (2000) found a 
linear correlation between the wet mass peak torque and 
pellet size for pellet formulas containing 80 % (w/w) 
Avicel PH101.
In vitro release from pellets
Pellets containing Avicel PH101 showed fast release 
of DM. The release was complete within 30 minutes. 
Addition of polymers delayed this pattern of release. 
However, pellets containing 5, 10, and 20% EC showed a 
faster release of DM than the other two polymers, as shown 
in Figure 4. The T80% value was less than 30 minutes for 
the three tested formulae. 
Figure 5 shows the in vitro DM release from pellets 
containing HPMC. It was observed that increasing the 
level of HPMC from 5% to 20% slowed drug release. It 
was interesting that DM release from pellets containing 
20% HPMC was faster than that containing 10% HPMC. 
This observation could be explained on the basis of MTR 
results. In all formulations containing 20% polymer, 
there was a reduction in the binder ratio in contrast to that 
recorded with the system containing 5% or 10%, which 
could decrease the hydration of HPMC. DM release is 
controlled by the hydration of HPMC, which formed 
a gelatinous barrier layer at the surface of the matrix. 
Increasing HPMC concentration from 5 to 10% showed a 
decrease in DM release, in which (F5), 80% of DM was 
released after 30 minutes. 
The effect of Carbopol level on DM release is shown 
in Figure 6. The drug release decreased as the amount of 
Carbopol level in the pellets increased from 5 to 10%, 
relative to control. The T80% value (time for 80% DM 
release) was 20, 30, 55, and 30 minutes for F0 (control), 
F7, F8, and F9 (contain 5, 10, and 20% Carbopol), 
respectively. This could be attributed to the fact that the 
gel layer formed around the pellets became stronger with 
less regions of microviscosity as a result of the anionic 
character of Carbopol. 
On the basis of the above results, it was found that 
Carbopol polymer at 10% is more effective than cellulosic 
materials in sustaining the DM release when used at the 
same levels. Carbopol is a lightly crosslinked polymer, 
unlike the cellulosic materials, which are linear. In matrix 
pellets prepared with linear hydrophilic polymers (such 
as HPMC, which do not have a covalently crosslinked 
structure), a gelatinous layer is formed on the surface of 
the pellets on hydration. On the other hand, the crosslinked 
network of Carbopol enables the entrapment of drug in the 
hydrogel domain. These hydrogels erode slower than linear 
TABLE II -Volume weighted mean particle size and the d(0.1), d(0.5), d(0.9) and span values of different pellet formulae loaded 
with DM (10%w/w as determined by laser diffractometry)
Pellets Formulation Mean (μm) D (0.1) μm d (0.5) μm d (0.9) μm Span value
F0 1032.5 670.4 1020.5 1411.2 0.73
F1 974.5 525.4 987.6 1385.4 0.87
F2 912.5 485.4 895.4 1305.4 0.91
F3 878.5 465.7 877.4 1289.7 0.94
F4 1175.5 690.4 1089.4 1511.1 0.62
F5 1235.4 728.5 1132.7 1568.4 0.74
F6 1248.6 720.1 1115.4 1420.1 0.81
F7 1098.5 697.4 1112.4 1487.5 0.71
F8 1242.7 718.7 1164.2 1518.4 0.69
F9 ND ND ND ND ND
F10 1280.5 780.6 1203.6 1590.4 0.71
F11 1260.3 760.4 1150.3 1476.7 0.80
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polymers (Khan, Jiabi, 1998). Figure 7 shows the effect of 
blending Carbopol 934 and HPMC K15M (1:1) on the in 
vitro release of DM. Combination of Carbopol and HPMC 
at different proportions (5 and 10%) significantly (P < 0.05) 
retarded the release of DM, relative to Carbopol or HPMC 
alone (F10, F11). These data show that a combination of 
anionic polymer (Carbopol 934) and nonionic HPMC 
produce a synergistic effect in delay of DM release. The 
T80% value increased from 30 min(F5) and 55 minutes 
(F6) to 150 minutes (F10). This is likely due to stronger 
hydrogen bonding between the carboxyl groups of Carbopol 
and the hydroxyl groups of HPMC, leading to stronger 
crosslinking between the two polymers, and a synergistic 
increase in viscosity. This is reflected in the increased 
mean line torque value of pellet wet mass for formulations 
containing either Carbopol or HPMC, relative to those 
containing EC. Therefore, a noticeable inhibition of drug 
release was exerted by the matrix pellet formulations 
containing Carbopol and HPMC. Samani, Montaseri and 
Kazemi (2003) showed that a combination of anionic 
polymer Carbopol 940 with nonionic HPMC produced a 
synergistic increase in viscosity. The authors attributed this 
finding to the stronger hydrogen bonding between carboxyl 
groups of Carbopol and hydroxyl groups of HPMC, leading 
to a stronger crosslinking between the two polymers, 
diminishing fluctuations in drug release. This behavior of 
HPMC and Carbopol blend has been also reported by Rao, 
Veni and Jayasagar (2001) and Anlar et al. (1994). These 
studies reported that an interpolymer complex was formed in 
solution between HPMC and Carbopol, and they attributed 
this phenomenon to an interaction between hydroxyl groups 
of HPMC and carboxyl groups of Carbopol. In our previous 
study, we found such interaction and elucidated it using IR 
spectroscopy. The results of IR spectra for Carbopol–HPMC 
physical mixture in comparison with Carbopol–HPMC 
matrix after soaking confirmed these suggestions (Fayed 
et al., 2011).
Kinetic modeling of the in vitro release data
In order to determine the release model which best 
describes the pattern of drug release, the in‑vitro release 
data were fitted to zero order, first order (Martin, 1993) 
and diffusion controlled release mechanisms according to 
FIGURE 4 ‑ In vitro release profiles of DM from pellets 
formulations prepared from different EC concentrations.
FIGURE 5 ‑ In vitro release profiles of DM from pellets 
formulations prepared from different HPMC K10 concentrations.
FIGURE 6 ‑ In vitro release profiles of DM from pellets 
formulations prepared from different carbopol concentrations.
FIGURE 7 ‑ In vitro release profiles of DM from pellets 
formulations F10 and F11 compared to F0.
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the simplified Higuchi model (Higuchi, 1962).
a- Zero‑order Kinetic model: 
C=Co‑ Ko t. 
b- First‑order Kinetic model: 
log C = log Co‑Kt/2.303 
c- Higashi diffusion model: 
Q= 2 Co (Dt/π)½ 
where: Co= initial drug concentration; C= drug 
concentration (remaining) at time t; t= time of release; 
Q= amount of drug released/unit area; Ko= zero order 
rate constant, K= first order rate constant and D=diffusion 
Coefficient and it was calculated according to the 
following equation.
D= (Slope/2Co) 2 π
The preference of a certain mechanism was based on 
the correlation coefficient (r) for the parameters studied, 
where the highest correlation coefficient is preferred for the 
selection of mechanism of release (Samuelov et al., 1979)
Successive evidence of the relative validity of 
diffusion and first order models obtained by analyzing the 
data using the following equation (Ritger, Peppas, 1987). 
Mt/M∞=K.t1/2
where Mt/M∞ is the fraction released by the drug at time 
t, K is a constant incorporating structural and geometric 
characteristic and n is the release exponent characteristic 
for the drug transport mechanism. When n=0.5, Fickian 
diffusion is observed and the release rate in dependent 
on t, while 0.5<n<1.0 indicate anomalous (non Fickian) 
transport and when n=1, the release is zero order.
The mathematical treatment of the vitro release data 
of DM from the prepared pellets are presented in Table III. 
Based on the correlation coefficient values (r), the results 
of the formulations that showed rapid release rate (biphasic 
first order), while the formulations containing polymer 
combination showed an anomalous non‑Fickian release 
as indicated from the n values. 
CONCLUSION
DM sustained release matrix pellets containing 
10% w/w drug with extended release were successfully 
prepared by extrusion/spheronization technique. 
The effect of mixing different concentrations of EC, 
HPMC K10, and Carbopol 934 with Avicel PH101 
on the rheological properties of pellet wet mass 
demonstrated that increasing the mixed concentration of 
the hydrophobic polymer (EC) with Avicel PH101 caused 
a reduction in wet mass consistency. Lower binder ratio 
was required for optimum wet massing, while mixing 
the swellable polymers, HPMC and Carbopol, caused a 
noticeable increase in both the mean torque and binder 
ratio. The average pellet sizes were found in the range of 
878-1280 μm. An inverse proportionality was observed 
between wet mass mean line torque and pellets’ sizes. 
The wet mass characteristics of the prepared pellets had a 
pronounced impact on the in vitro DM release rate. it was 
found that Carbopol polymer at 10% is more effective 
than cellulosic materials in sustaining the DM release, 
when used at the same levels. 
 Moreover, combination of HPMC and Carbopol 
resulted in improved control of the in vitro release rate 
of DM. The results showed that a combination of anionic 
polymer (Carbopol 934) and nonionic HPMC produced 
a synergistic effect in delaying DM release Furthermore, 
the mathematical treatment of the vitro release data of 
TABLE III - Kinetic modeling of drug release form pellets containing DM
Release Model
Pellet Formulations
F2 F5 F8 F10 F11
Zero order
r 0.756 0.786 0.879 0.913 0.867
Ko (mg%/min) 0.687 0.686 0.670 0.570 0.623
First order
r 0.947 0.964 0.975 0.976 0.956
K1 (min-1) x103 35.66 34.8 33.6 9.2 14,95
Higuchi diffusion
r 0.912 0.925 0.979 0.991 0.972
Kh(mg%)/min1/2 9.17 9.10 9.73 6.83 7.90
Log Q Vs log t
r 0.955 0.966 0.979 0.995 0.988
n 0.09 0.10 0.30 0.40 0.25
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DM from the prepared pellets showed an anomalous non‑
Fickian release. 
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